Clinical Trial Update: Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating BOS-589 for diarrhea-predominant irritable bowel syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diarrhea-predominant Irritable Bowel Syndrome
• Irritable Bowel Syndrome

Drugs mentioned

• BOS-589

Snippet

Sponsor: Boston Pharmaceuticals | Conditions: Diarrhea-predominant Irritable Bowel Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2021-06-07